References:

• Abotaleb, M., Kubatka, P., Caprnda, M., Varghese, E., Zolakova, B., Zubor, P., Büsselberg, D. (2018). Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. Biomedicine & Pharmacotherapy., 101, 458-477.
• Abraham, J., & Staffurth J (2016). Hormonal therapy for cancer. Medicine., 44, 30-33.
• Ayer, T. (2015). Inverse optimization for assessing emerging technologies in breast cancer screening. Ann Oper Res., 230(1), 57‐85.
• Barenholz, Y.C. (2012). Doxil-the first FDA-approved nano-drug: lessons learned. J Control Release., 160 (2), 117-134.
• Bartlett, J.M.S., Sgroi, D.C., Treuner, K., Zhang, Yi., Piper, T., Salunga, R.C., Ahmed, I., Doos, L., Thornber, S., Taylor, K.J., Brachtel, E.F., Pirrie, S.J., Schnabel, C.A., Rea, D.W. (2022). Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. Clin Cancer Res., 2, 28(9),1871-1880.
• Bodewes, F. T. H., van Asselt, A. A., Dorrius, M. D., Greuter, M. J. W., de Bock, G. H. (2022). Mammographic Breast Density and the Risk of Breast Cancer: A Systematic Review and Meta-Analysis. Breast, 66, 62– 68.
• Brisken, C., & O’Malley, B. (2010). Hormone action in the mammary gland. Cold Spring Harb Perspect Biol., 2(12), a003178.
• Broët, P., Scholl, S.M., de la, Rochefordière., A., Fourquet, A., Moreau, T., De Rycke., Y., Asselain, B., Pouillart, P. (1999). Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: An updated analysis of a randomized trial. Breast Cancer Res. Treat, 58, 151-156.
• Caulfield, S. E., Davis, C. C., Byers, K. F. (2019). Olaparib: A novel therapy for metastatic breast cancer in patients with a BRCA1/2 mutation. J. Adv. Pract. Oncol. 10(2), 167-174.
• Chan, A., Delaloge, S., Holmes, F.A., Moy, B., Iwata, H., Harvey, V.J., Robert, N.J., Silovski, T., Gokmen, E., von Minckwitz, G., et al (2016). Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 17, 367–377.
• Charafe-Jauffret, E., Ginestier, C., Monville, F., Finetti, P., Adelaide, J., Cervera, N. et al (2006). Gene expression profiling of breast cancer cell lines identifies potential new basal markers. Oncogene., 25, 2273-84.
• Chaurasia, M., Singh, R., Sur, S. & Flora, S. J. S. (2023). A review of FDA approved drugs and their formulations for the treatment of breast cancer. Front Pharmacol., 14.
• Chira, C., Kirova, Y.M., Liem, X., Campana, F., Peurien, D., Amessis, M., Fournier-Bidoz, N., Pierga, J.Y., Dendale, R., Bey, P., et al (2013). Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool. Bio Med Res. Int, 264306.
• Cutuli, B., Lafontan, B.D., Kirova, Y., Auvray, H., Tallet, A., Avigdor, S., Brunaud, C., & Delva, C. (2015) . Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases. Radiation Oncology., 10, 110.
• Davies, C., Pan, H., Godwin, J., et al (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet., 381(9869), 805–816.
• Dirix, L.Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H.T., Forero-Torres, A., Boccia, R., Lippman, M.E., Somer, R., Smakal, M., et al (2018). Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN Solid Tumor study. Breast Cancer Res. Treat., 167, 671-686.
• Elizabeth, M Ward., Carol, E DeSantis., Chun, Chieh Lin., Joan, L Kramer , Ahmedin Jemal , Betsy Kohler , Otis, W Brawley., Ted, Gansler (2015). Cancer statistics: Breast cancer in situ. CA Cancer J Clin., 65(6), 481-95.
• Emens, L.A., Cruz, C., Eder, J.P., Braiteh, F., Chung, C., Tolaney, S.M., Kuter, I., Nanda, R., Cassier, P.A., Delord, J.P., et al (2019). Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients with Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol., 5, 74-82.
• Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E.R., Wickerham, D.L., Begovic, M., DeCillis, A., Robidoux, A., et al (1998). Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol., 16, 2672-2685.
• Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N (2009). Triple-negative breast cancer–current status and future directions. Ann Oncol., 20, 1913–1927.
• Guan, H., Wan, H., Lan, J., Wang, Q., Wang, Z., Li, Y., Zheng, J., Zhang, X., Wang, Z., Shen, Y., & Xie, F. (2016). PD‐L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer. Sci Rep., 6, 35651.
• Hammond, M.E.H., Hayes, D.F., Dowsett, M., Allred, D.C., Hagerty, K.L., Badve, S., Fitzgibbons P.L., Francis, G., Goldstein, N.S., Hayes, M., et al (2010). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J. Clin. Oncol., 28, 2784-2795.
• Heimes, A. S., & Schmidt, M. (2018). Atezolizumab for the treatment of triple-negative breast cancer. Expert Opin Investig Drugs., 28, 1-5.
• Hernandez-Aya, L. F., & Ma, C. X. (2016). Chemotherapy principles of managing stage IV breast cancer in the United States. Chinese Clinical Oncology., 5(3), 13.
• Inwald, E.C., Klinkhammer-Schalke, M., Hofstädter, F., Zeman, F., Koller, M., Gerstenhauer, M., & Ortmann, O. (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat., 139(2), 539-552.
• Jacobs, A.T., Castaneda-Cruz D.M., Rose, M.M., Linda Connelly (2022). Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochemical Pharmacology., 204, 115209.
• Karlitepe A., Ozalp O., & Avci C.B (2015). New approaches for cancer immunotherapy. Tumour Biol., 36(6), 4075–4078. Kerlikowske, K., Hubbard, R.A., Miglioretti, D.L., Galler B.M, Yankaskas B.C., Lehman, C.D., Taplin, S.H., & Sickles, E.A. (2011). Breast Cancer Surveillance Consortium. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med., 155(8),493-502.
• Kroese, M., Zimmern, R.L., Pinder, S.E. (2007). HER2 status in breast cancer—an example of pharmacogenetic testing. J R Soc Med., 100(7), 326–329.
• Le, N.F., Misek, D.E., Krause, M.C., Deneux, L., Giordano, T.J., Scholl, S., Hanash, S.M. (2001). Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin. Cancer Res., 7, 3328–3335.
• Li, CI., Uribe, D.J., Daling, J.R. (2005). Clinical characteristics of different histologic types of breast cancer. Br J Cancer., 93, 1046–1052.
• Lumachi, F., Luisetto, G., Basso, S.M.M., Basso, U., Brunello, A., Camozzi, V. (2011). Endocrine Therapy of Breast Cancer. Curr. Med. Chem., 18, 513–522.
• Maji, R., Dey, N. S., Satapathy, B. S., Mukherjee, B., Mondal, S. (2014). Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy. Int. J. nanomedicine., 9, 3107–3118.
• Mercogliano, M.F., Bruni, S., Mauro, F.L., & Schillaci, R. (2023). Emerging Targeted Therapies for HER2-Positive Breast Cancer. Cancers (Basel)., 15(7), 1987.
• Michael, F., Walsh, Katherine L. Nathanson., Fergus J. Couch., & Kenneth, Offit. (2016). Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol., 882, 1–32.
• Minckwitz, Von G., Martin, M., Wilson, G., et al (2013). Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. Crit Rev Oncol Hematol., 85(3), 315–331.
• Montesinos, P.B., Soriano-Teruel, P.M., Armiñán, A., Orzáez, M., Vicent, M.J. (2021). The past, present, and future of breast cancer models for nanomedicine development. Advanced Drug Delivery Reviews., 173, 306-330.
• Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T., et al (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer cell., 10, 515-27.
• Nuciforo, P., Radosevic-Robin, N., Ng, T., Scaltriti, M. (2015). Quantification of HER family receptors in breast cancer. Breast Cancer Res., 17, 53.
• Onitilo, A.A., Engel, J.M., Greenlee, R.T., Mukesh, B.N. (2009). Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res., 7(1-2), 4-13.
• Palmer, M.L. & Tsangaris, T.N. (1993). Breast biopsy in women 30 years old or less. Am J Surg., 165(6), 708-712.
• Pareek, A., Singh, O.P., Yogi, V., Ghori, H.U., Tiwari, V., Redhu, P. (2019). Bone metastases incidence and its correlation with hormonal and human epidermal growth factor receptor 2 neu receptors in breast cancer. J Cancer Res Ther., 15(5), 971-5.
• Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H.C., Clarke, M., Cutter, D., Darby, S., McGale P. Taylor, C., Wang, Y.C., Bergh, J., Di Leo, A., Albain, K., Swain, S., Piccart, M,, Pritchard, K. (2012). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet., 379, 432-444.
• Puhalla, S., Brufsky, A., Davidson, N. (2009). Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast., 18(suppl 3), S122-S130.
• Reed, A.E.M., Kalinowski, L., Simpson, P.T., & Lakhani, S.R. (2021). Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Res., 23, 6.
• Rivera, E., & Gomez, H. (2010). Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res.,12(Suppl 2), S2.
• Roy, P., Sur, S., Das, S., Tin, W. (2022). Phytochemical-conjugated bio-safe gold nanoparticles in breast cancer. A comprehensive update. Breast Cancer, 29, 761-777.
• Sabatier, R., Finetti, P., Mamessier, E., et al (2015). Prognostic and predictive value of PDL1 expression in breast cancer. Onco target., 6, 5449-5464.
• Salkeni, M.A., & Hall, S.J. (2017). Metastatic breast cancer: Endocrine therapy landscape reshaped. Avicenna J Med., 7(4), 144-152.
• Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J.L., Pedersen, K., Smith, D.J., Landolfi, S., Ramony Cajal, S., Arribas, J., Baselga, J. (2009). Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene., 28, 803-814.
• Shao, N., Wang, S., Yao, C., Xu, X., Zhang, Y., Zhang, Y., & Lin, Y. (2012). Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials. Breast., 21(3), 389-393.
• Steger, G.G., & Bartsch, R. (2011). Denosumab for the treatment of bone metastases in breast cancer: Evidence and opinion. Ther. Adv. Med. Oncol., 3, 233-243.
• Tremont, A., Lu J., & Cole J.T (2017). Endocrine Therapy for Early Breast Cancer: Updated Review. Ochsner J., 17, 405-411.
• van der Hage, J.A., van de Velde, C.J., Julien, J.P., Tubiana-Hulin, M., Vandervelden, C., Duchateau, L (2001). Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J. Clin. Oncol., 19, 4224-4237.
• Voli, L. A., Mamyrbékova J. A., Bazureau J.-P. (2020). Abemaciclib, a recent novel FDA-approved small molecule inhibiting cyclin-dependant kinase 4/6 for the treatment of metastatic breast cancer: A mini-review. Open J. Med. Chem., 10 (03), 128-138.
• Witton, C.J., Reeves J.R., Going J.J., Cooke T.G., Bartlett J.M.S (2003). Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol., 200, 290-297.
• Wolff, A.C., Hammond M.E.H., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., Allred D.C., Bartlett J.M.S., Bilous M., Fitzgibbons P., et al (2014). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch. Pathol. Lab. Med., 138, 241-256.
• Wong, H. L., Rauth A. M., Bendayan R., Manias J. L., Ramaswamy M., Liu Z., et al. (2006). A new polymer–lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm. Res., 23, 1574-85.
• Yang, T.J., & Ho, A.Y. Radiation Therapy in the Management of Breast Cancer (2013). Surg. Clin. N. Am., 93, 455-471.